FDA Grants Accelerated Approval to Elranatamab-bcmm for Relapsed or Refractory Multiple Myeloma
August 14th 2023Elranatamab-bcmm (Elrexfio; Pfizer) is a BCMA-CD3-targeted bispecific antibody approved for adults with relapsed or refractory multiple myeloma who were previously administered at least 4 lines of therapy that included a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Read More
Simulation Demonstrates Potential Effectiveness of Model-Informed Precision Dosing for Heparin
August 14th 2023The growing awareness in health care of the challenges associated with proper dosing of anticoagulants such as heparin has inspired the emerging field of anticoagulation stewardship.
Read More
Driving Patient Safety With New Pharmacy HIT Standards
August 11th 2023New standards from the National Council for Prescription Drug Programs could drive changes that improve patient safety by optimizing drug therapy to reduce the risk of harm and improve health and well-being before a medication is dispensed.
Read More